Skba Capital Management LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Skba Capital Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 15.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,150 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Skba Capital Management LLC’s holdings in Pfizer were worth $658,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PFE. Franklin Resources Inc. boosted its position in shares of Pfizer by 28.8% in the 3rd quarter. Franklin Resources Inc. now owns 45,980,291 shares of the biopharmaceutical company’s stock valued at $1,977,614,000 after purchasing an additional 10,270,562 shares during the period. Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Pfizer by 470.3% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 10,012,954 shares of the biopharmaceutical company’s stock worth $430,657,000 after purchasing an additional 8,257,100 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Pfizer by 215.5% during the third quarter. Renaissance Technologies LLC now owns 7,457,601 shares of the biopharmaceutical company’s stock worth $320,751,000 after acquiring an additional 5,093,860 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $262,207,000. Finally, TD Asset Management Inc. boosted its position in shares of Pfizer by 116.0% during the fourth quarter. TD Asset Management Inc. now owns 7,806,890 shares of the biopharmaceutical company’s stock worth $460,997,000 after buying an additional 4,192,157 shares during the period. Institutional investors and hedge funds own 66.50% of the company’s stock.

Several analysts recently issued reports on PFE shares. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Citigroup boosted their price target on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. The Goldman Sachs Group set a $51.00 price target on shares of Pfizer in a research report on Wednesday, May 4th. Berenberg Bank set a $50.00 price target on shares of Pfizer in a report on Thursday, April 21st. Finally, BMO Capital Markets lifted their price objective on shares of Pfizer from $60.00 to $76.00 in a research note on Friday, January 14th. Eleven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.05.

PFE stock traded up $0.94 on Thursday, reaching $50.39. 33,397,801 shares of the company’s stock were exchanged, compared to its average volume of 31,609,309. The company has a quick ratio of 1.19, a current ratio of 1.40 and a debt-to-equity ratio of 0.47. The firm has a market cap of $284.59 billion, a PE ratio of 11.56, a P/E/G ratio of 0.76 and a beta of 0.76. Pfizer Inc. has a twelve month low of $38.47 and a twelve month high of $61.71. The stock has a fifty day moving average of $51.23 and a 200-day moving average of $51.80.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing the consensus estimate of $1.80 by ($0.18). The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.93 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 6.74 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 dividend on an annualized basis and a yield of 3.18%. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.